code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf doxazosin 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold quinazoline.

and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to doxazosin high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a doxazosin release form of doxazosin, to doxazosin marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a doxazosin release form of doxazosin, to be marketed as doxazosin XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a doxazosin release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which inhibits the binding of norepinephrine to alpha receptors doxazosin the autonomic nervous system. The primary effect of this blockage is relaxed vascular smooth muscle tone (vasodilation), which doxazosin peripheral vascular resistance.

peripheral vascular resistance, leading to decreased blood pressure.[edit] External links.